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Background
Clinical studies suggest that adoptive transfer of allo-
geneic natural killer (NK) cells represent a promising
treatment for patients with hematological malignancies
and solid tumors. Celgene Cellular Therapeutics has
established a cultivation process to generate human NK
cells from umbilical cord blood (UCB) CD34+ cells with
substantial cytolytic activity against several human
tumor cell lines.
Method
UCB CD34+ cells were cultivated in presence of cytokines
including thromobopoietin, SCF, Flt3 ligand, IL-7, IL-15
and IL-2 for 35 days to produce Placental Intermediate
Natural Killer (PiNK) cells. Multi-color flow cytometry
was used to determine the phenotypic characteristics of
PiNK cells. Cytotoxicity assays were performed by co-
culturing PiNK cells with tumor cell lines for 4 hours.
Furthermore, supernatants were collected to analyze
secreted perforin, granzymes and cytokines.
Results
Using the cultivation process, a highly pure population
(88.3% ± 6.3%) of CD3-CD56+ NK cells was routinely
achieved. PiNK cells display a developmentally intermedi-
ate immunophenotype, evidenced by the low / negative
expression of CD16 and KIRs. PiNK cells express the nat-
ural cytotoxicity receptors (NKp30, NKp46 and NKp44),
the c-lectin receptors (CD94, NKG2D and CD161),
DNAM-1, 2B4, CD117, and CD11a. Cytolytic mediators
(perforin and granzymes) and Eomes, the regulator of
NK cell maturation and cytolytic function, were detected
in PiNK cells. PiNK cells exhibit cytotoxicity against
hematological tumor cell lines in vitro. At an effector to
target ratio of 10:1, PiNK cells exert lysis towards cell
lines, including CML (K562, 70.3% ± 14.8%), AML (HL-
60, 31.0% ± 17.8%) and multiple myeloma (RPMI8266,
32.4% ± 19.5%). When co-cultured with K562 cells at a
1:1 ratio for 24 hours, PiNK cells produce functional
cytokines including IFN-g, TNF-a and GM-CSF. Confo-
cal imaging revealed that PiNK cells, when in contact
with tumor cells, formed an F-actin immunological
synapse with polarization of perforin. Furthermore, in the
presence of anti-CD20 (Rituximab, 10 mg/mL), the cyto-
toxicity of PiNK cells against Daudi cells (Burkitt’s lym-
phoma) increased from 7.3% ± 8.0% to 35.1% ± 5.7%,
demonstrating potent antibody-dependent cell-mediated
cytotoxicity (ADCC).
Conclusions
Large quantities of functionally active PiNK cells can be
generated from UCB CD34+ progenitors. These cells elicit
anti-tumor activity via direct cytolysis, ADCC, and secreted
effector cytokines. PiNK cells represent an allogeneic cellu-
lar immunotherapy product with potential applications for
patients with hematologic malignancies and solid tumors.
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